在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

Human Folate receptor alpha(FOLR1) ELISA kit

  • 中文名稱:
    人葉酸受體α(FOLR1)酶聯免疫試劑盒
  • 貨號:
    CSB-EL008784HU
  • 規格:
    96T/48T
  • 價格:
    ¥3600/¥2500
  • 其他:

產品詳情

  • 產品描述:
    人葉酸受體α(FOLR1)酶聯免疫試劑盒(CSB-EL008784HU)為雙抗夾心法ELISA試劑盒,定量檢測血清、血漿、組織勻漿樣本中的FOLR1含量。FOLR1 即葉酸受體 1,是一種膜結合蛋白,在多種惡性腫瘤中高表達,而在正常組織中低表達或不表達。其研究機制主要聚焦于利用它與葉酸的高親和力,開發靶向藥物、診斷試劑等,以實現腫瘤的精準治療和早期診斷。試劑盒檢測范圍為0.39 ng/ml- 25 ng/ml,靈敏度為0.09 ng/ml。適用于探索FOLR1在卵巢癌、肺癌等實體瘤中的表達模式,評估腫瘤微環境中的生物標志物動態變化,或用于葉酸代謝相關藥物的體外研究;為研究FOLR1在細胞信號傳導、疾病機制及治療靶點篩選等科研領域提供可靠工具本品僅用于科研,不用于臨床診斷,產品具體參數及操作步驟詳見產品說明書。
  • 別名:
    adult ELISA Kit; Adult folate binding protein ELISA Kit; Adult folate-binding protein ELISA Kit; FBP ELISA Kit; Folate Binding Protein ELISA Kit; Folate Receptor 1 Adult ELISA Kit; Folate receptor 1 ELISA Kit; Folate Receptor 1 Precursor ELISA Kit; Folate receptor adult ELISA Kit; Folate receptor alpha ELISA Kit; Folate receptor ELISA Kit; FOLR ELISA Kit; FOLR1 ELISA Kit; FOLR1_HUMAN ELISA Kit; FR alpha ELISA Kit; FR-alpha ELISA Kit; FRalpha ELISA Kit; KB cells FBP ELISA Kit; MOV18 ELISA Kit; Ovarian cancer associated antigen ELISA Kit; Ovarian tumor associated antigen ELISA Kit; Ovarian tumor associated antigen MOv18 ELISA Kit; Ovarian tumor-associated antigen MOv18 ELISA Kit
  • 縮寫:
  • Uniprot No.:
  • 種屬:
    Homo sapiens (Human)
  • 樣本類型:
    serum, plasma, tissue homogenates
  • 檢測范圍:
    0.39 ng/ml - 25 ng/ml
  • 靈敏度:
    0.09 ng/ml
  • 反應時間:
    1-5h
  • 樣本體積:
    50-100ul
  • 檢測波長:
    450 nm
  • 研究領域:
    Tags & Cell Markers
  • 測定原理:
    quantitative
  • 測定方法:
    Sandwich
  • 精密度:

    Intra-assay Precision (Precision within an assay): CV%<8%

    Three samples of known concentration were tested twenty times on one plate to assess.

    Inter-assay Precision (Precision between assays): CV%<10%

    Three samples of known concentration were tested in twenty assays to assess.

  • 線性度:

    To assess the linearity of the assay, samples were spiked with high concentrations of human FOLR1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

     

    Sample

    Serum(n=4)

    1:1

    Average %

    92

    Range %

    88-97

    1:2

    Average %

    98

    Range %

    91-104

    1:4

    Average %

    90

    Range %

    83-97

    1:8

    Average %

    95

    Range %

    88-102

  • 回收率:

    The recovery of human FOLR1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

    Sample Type

    Average % Recovery

    Range

    Serum (n=5)

    98

    91-104

    EDTA plasma (n=4)

    93

    88-97

  • 標準曲線:

    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

    ng/ml

    OD1

    OD2

    Average

    Corrected

    25

    2.715

    2.634

    2.674

    2.553

    12.5

    2.072

    2.167

    2.119

    1.998

    6.25

    1.360

    1.328

    1.344

    1.223

    3.12

    0.821

    0.839

    0.830

    0.709

    1.56

    0.477

    0.491

    0.484

    0.363

    0.78

    0.293

    0.303

    0.298

    0.177

    0.39

    0.192

    0.184

    0.188

    0.067

    0

    0.117

    0.125

    0.121

     

  • 數據處理:
  • 貨期:
    3-5 working days

產品評價

靶點詳情

  • 功能:
    Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release. Required for normal embryonic development and normal cell proliferation.
  • 基因功能參考文獻:
    1. This study demonstrated a new approach using a combination of EpCAM and FRalpha as CTC-capture targets to increase the sensitivity of CTC detection in NSCLC efficiently, specifically, and quickly. PMID: 29352248
    2. Several experimental studies in mice and human epidemiological and genetics studies have suggested that FOLR1 abnormalities are involved in a portion of human neural tube defects (NTD), although the solo defect of FOLR1 did not cause NTD. (Review) PMID: 28244241
    3. that FOLR1 is highly expressed in ovarian cancer but is reduced following multidrug resistance. FOLR1 may be a useful biomarker for ovarian cancer, and it may be useful as a therapeutic application to improve sensitivity to cisplatin treatment PMID: 29433550
    4. mTORC1 or mTORC2 silencing markedly decreases the plasma membrane expression of FR-alpha and RFC transporter isoforms without affecting global protein expression PMID: 27562465
    5. High Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer. PMID: 28410844
    6. The expression of folate receptor 1 (FOLR1) was significantly higher and occurred with higher frequency in metastatic lymph node samples from patients with advanced lung cancer. PMID: 29110850
    7. We identified eight novel variants in SLC19A1 and twelve novel variants in FOLR1, FOLR2, and FOLR3. Pathogenic variants include c.1265delG in SLC19A1 resulting in an early stop codon, four large insertion deletion variants in FOLR3, and a stop_gain variant in FOLR3 PMID: 28948692
    8. In this study, folate receptor alpha (FRa)-targeted nano-liposomes (FLP) were designed to enhance the anti-tumor effect by targeting delivery of exogenous PEDF gene to cervical cancer cells..These results clearly showed that FLP were desired carriers for PEDF gene and FLP/PEDF might represent a potential novel strategy for gene therapy of cervical cancer. PMID: 27576898
    9. Data show that higher folate receptor alpha (FRalpha) expression is predictive of a favorable prognosis in pancreatic ductal adenocarcinoma (PDAC) and FRalpha may represent a promising target for treatments. PMID: 28430580
    10. our results demonstrate the substantial therapeutic potential of novel 6-substituted pyrrolo[2,3-d]pyrimidine antifolates with dual targeting of PCFT and FRalpha toward Epithelial ovarian cancer that express a range of FRalpha, along with PCFT, as well as cisplatin resistance PMID: 28138029
    11. Low expression level of FOLR1 is associated with neuroendocrine lung tumors. PMID: 27064343
    12. FolR1 is a predictive candidate and a therapeutic target for medulloblastoma. PMID: 28416738
    13. Folr1 is a favorable target for fluorescence-guided surgery as tumor specific agent EC17 produced a clear fluorescent signal in ovarian and breast cancer tissue. PMID: 27014973
    14. The Folate receptor alpha is associated with the progression of cervical cancer and regulates cervical cancer cells growth through phosphorylating ERK1/2, c-Fos, and c-Jun, which are key factors of the ERK signaling pathway. PMID: 28782518
    15. Folate receptor alpha protein was expressed in the majority of lung adenocarcinomas and a minority of lung squamous cell carcinomas. Folate receptor alpha protein expression correlated with histologic grade for lung adenocarcinomas, and the greatest difference was observed between grade 1 and grade 3. PMID: 26599808
    16. The present study shows the efficacy of silencing HuR in lung cancer cells using folate-conjugated nanoparticle system that is directed towards folate receptor-alpha overexpressing cancer cells. PMID: 27328938
    17. This new protocol opens an effective way through synthesis and design of novel fluorescent nano-conjugates for FR expression investigation in tumor cells via targeted imaging, showing great potential in drug delivery mechanism study and cancer therapy PMID: 26606305
    18. Suppression of FOLR1 by RNA interference altered gene expression profile of taxol-resistant nasopharyngeal carcinoma cells. Apoptosis-related genes, gene alterations in viral carcinogenesis/MAPK pathways may be important for taxol resistance reversal. PMID: 26617855
    19. we confirmed the similarities between epithelial ovarian cancer and fallopian tube, normal and adenocarcinoma using FOLR1, FOLR2, CD68 and CD11b markers PMID: 25971554
    20. Suggest RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor-alpha. PMID: 26359629
    21. Folate receptor expression on murine and human adipose tissue macrophages PMID: 26149693
    22. Findings suggest the clinical development of IMGN853 as a novel targeted therapy for patients with folate receptor alpha (FRalpha)-expressing tumors. PMID: 25904506
    23. Suggest that FRalpha overexpression may play a role in the endometrioid endometrium carcinoma carcinogenesis and carcinoma progression from endometrial hyperplasia. PMID: 26191275
    24. triple negative/basal tumors were significantly associated with increased expression of FOLR1 mRNA, compared to ER+ and HER2+ tumors. PMID: 25816016
    25. Molecular dynamic simulation of the binding process of folic acid to folate receptor alpha PMID: 25323390
    26. Studies indicate folate receptor (FR) as a prognostic biomarker for ovarian cancer. PMID: 25564455
    27. The overexpression of folate receptor alpha mRNA was associated with growth of pituitary adenomas. PMID: 26014017
    28. this is the first study to simultaneously evaluate both DNA methylation and protein expression of all three folate transporter genes, FOLR1, PCFT, and RFC1, in colorectal cancer. PMID: 25697897
    29. FRalpha down-regulation might be capable of suppressing cervical cancer cell proliferation and promoting apoptosis. PMID: 25081683
    30. Survival times are improved in non-small-cell lung cancer patients whose tumors show strong membranous folate receptor alpha expression. PMID: 24993594
    31. the conditions associated with circulating FOLR1 protein in healthy individuals PMID: 24810481
    32. We concluded that quantitation of CTCs through FRalpha ligand-PCR could be a promising method for noninvasive diagnosis of bladder TCC. PMID: 24771263
    33. 74% of ER/PR-negative and 80% of triple-negative breast cancers expressed folate receptor alpha (FRA). The expression of FRA was significantly associated with a worse disease-free survival. PMID: 24028341
    34. Expression of FOLR1 is higher in pituitary adenomas of patients who are older than 50 years. PMID: 23023342
    35. FOLR1 was significantly elevated in the serum of ovarian cancer patients compared to serum of both healthy controls and patients with benign gynecological conditions. PMID: 23528302
    36. The FRalpha gene was expressed in all parathyroid cells analyzed, and the FRbeta gene was expressed by most. PMID: 24206618
    37. crystal structure of human FRalpha in complex with folic acid at 2.8 A resolution PMID: 23851396
    38. The data presented further support the hypothesis that folate receptor-alpha expression in gynecologic tumors is due to the cell of origin normally expressing this receptor PMID: 23518909
    39. EpCAM, FR-alpha, and VEGF-A are the most promising molecules for use in targeted intraoperative fluorescence imaging of endometriotic lesions owing to their favorable expression patterns and biomarker characteristics PMID: 23332132
    40. Studies indicate that folate receptor alpha (FOLR1), a folate transporter, is an attractive target for cancer therapy due to its high affinity for folate, restricted range of expression in normal tissue and differential over-expression in malignant tissue. PMID: 23357463
    41. Overexpression of folate receptor alpha was associated with ovarian tumor progression. PMID: 23144806
    42. The folate receptor alpha translocates to the nucleus, where it binds to cis-regulatory elements at promoter regions of Fgfr4 and Hes1, and regulates their expression. PMID: 23243496
    43. a large percentage of lung cancers, including squamous cell carcinomas in addition to adenocarcinomas, strongly express folate receptor alpha PMID: 22984810
    44. PCR analysis had confirmed the existence of FR-alpha, SMVT, and B ((0, +)) in Y-79 and ARPE-19 cells. PMID: 22304562
    45. High folate receptor alpha is associated with adenocarcinoma in non-small-cell lung carcinoma and and EGFR [corrected] mutation. PMID: 22729036
    46. alpha-FR can be a potential biomarker for the prediction of chemotherapeutic responses and clinical prognosis. PMID: 22265591
    47. studies suggest that different clinical severities do not necessarily correlate with residual function of folate receptor alpha mutants. PMID: 22586289
    48. FR-alpha was expressed in the majority of serous ovarian tumors, although >50% of cases showed only weak expression. PMID: 21647742
    49. FRalpha may play an important role in the development and progression of NFAs. PMID: 22089756
    50. An ancient double-mutated haplotype 1816delC-1841A in the FOLR1 gene, is demonstrated. PMID: 21938430

    顯示更多

    收起更多

  • 相關疾病:
    Neurodegeneration due to cerebral folate transport deficiency (NCFTD)
  • 亞細胞定位:
    Cell membrane; Lipid-anchor, GPI-anchor. Secreted. Cytoplasmic vesicle. Cytoplasmic vesicle, clathrin-coated vesicle. Endosome. Apical cell membrane. Note=Endocytosed into cytoplasmic vesicles and then recycled to the cell membrane.
  • 蛋白家族:
    Folate receptor family
  • 組織特異性:
    Primarily expressed in tissues of epithelial origin. Expression is increased in malignant tissues. Expressed in kidney, lung and cerebellum. Detected in placenta and thymus epithelium.
  • 數據庫鏈接:

    HGNC: 3791

    OMIM: 136430

    KEGG: hsa:2348

    STRING: 9606.ENSP00000308137

    UniGene: Hs.73769



主站蜘蛛池模板: 欧美成aⅴ人高清ww| 久久人人97超碰爱香蕉| 老司机性色福利精品视频| 欧美在线观看免费专区| 国内露脸少妇精品视频| 国模裸体无码xxxx视频| 中文人妻熟妇乱又伦精品| 亚洲熟妇久久国产精品| 国语自产偷拍精品视频蜜芽| 亚洲a∨无码一区二区三区| 国产精品夜间视频香蕉| 曰本无码不卡高清av一二 | 日韩人妻中文无码一区二区三区| 18禁在线永久免费观看| 肉大捧一进一出免费视频| 国产成人亚洲综合图区| 爆乳喷奶水无码正在播放| 欧美日韩亚洲国内综合网 | 欧美肥婆姓交大片| 护士脱了内裤让我爽了一夜视频| 午夜福利视频极品国产83| 久久精品人人做人人综合| 四虎免费大片aⅴ入口| 毛片tv网站无套内射tv网站| 久久久久99精品成人品| 色综合天天综合网国产成人网| 国产精品v欧美精品∨日韩| 国产av国内精品jk制服| 中国老熟妇自拍hd发布| 一区一区三区产品乱码| 风韵丰满熟妇啪啪区老老熟妇| 亚洲暴爽av天天爽日日碰| 加勒比中文无码久久综合色| 亚洲精品一区国产精品| 天堂中文8资源在线8| 男人的天堂av社区在线| 尤物精品国产第一福利网站| 精品人妻av一区二区三区| 少妇白浆呻吟爽| 亚洲人成网站18禁止中文字幕| 久久久久无码国产精品一区 |